ENTRY       D12296                      Drug
NAME        Tebentafusp (USAN/INN);
            Tebentafusp-tebn;
            Kimmtrak (TN)
PRODUCT     KIMMTRAK (Immunocore Commercial LLC)
SEQUENCE    (Heavy chain)
            AIQMTQSPSS LSASVGDRVT ITCRASQDIR NYLNWYQQKP GKAPKLLIYY TSRLESGVPS
            RFSGSGSGTD YTLTISSLQP EDFATYYCQQ GNTLPWTFGQ GTKVEIKGGG GSGGGGSGGG
            GSGGGGSGGG SEVQLVESGG GLVQPGGSLR LSCAASGYSF TGYTMNWVRQ APGKGLEWVA
            LINPYKGVST YNQKFKDRFT ISVDKSKNTA YLQMNSLRAE DTAVYYCARS GYYGDSDWYF
            DVWGQGTLVT VSSGGGGSDG GITQSPKYLF RKEGQNVTLS CEQNLNHDAM YWYRQDPGQG
            LRLIYYSWAQ GDFQKGDIAE GYSVSREKKE SFPLTVTSAQ KNPTAFYLCA SSWGAPYEQY
            FGPGTRLTVT EDLKNVFPPE VAVFEPSEAE ISHTQKATLV CLATGFYPDH VELSWWVNGK
            EVHSGVCTDP QPLKEQPALN DSRYALSSRL RVSATFWQDP RNHFRCQVQF YGLSENDEWT
            QDRAKPVTQI VSAEAWGRAD
            (Light chain)
            AQQGEEDPQA LSIQEGENAT MNCSYKTSIN NLQWYRQNSG RGLVHLILIR SNEREKHSGR
            LRVTLDTSKK SSSLLITASR AADTASYFCA TDGSTPMQFG KGTRLSVIAN IQKPDPAVYQ
            LRDSKSSDKS VCLFTDFDSQ TNVSQSKDSD VYITDKCVLD MRSMDFKSNS AVAWSNKSDF
            ACANAFNNSI IPEDT
            (Disulfide bridge: H23-H88, H153-H227, H281-H349, H401-H466, H427-L157, L23-L89, L132-L182)
  TYPE      Peptide
REMARK      ATC code: L01XX75
            Product: D12296<US>
EFFICACY    Antineoplastic
  DISEASE   Uveal melanoma (HLA-A*02:01-positive) [DS:H00038]
COMMENT     Fusion protein
            Treatment of uveal melanoma
TARGET      CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
            PMEL (gp100) [HSA:6490] [KO:K17304]
  PATHWAY   hsa04660(915+916+917)  T cell receptor signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XX Other antineoplastic agents
                 L01XX75 Tebentafusp
                  D12296  Tebentafusp (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antineoplastics, Other
               Tebentafusp
                D12296  Tebentafusp (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3
                 D12296  Tebentafusp (USAN/INN) &lt;US&gt;
             Not elsewhere classified
              Cellular process
               Membrane trafficking
                PMEL (gp100)
                 D12296  Tebentafusp (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12296
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12296
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12296
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D12296
DBLINKS     CAS: 1874157-95-5
///
